Charles River Laboratories International, Inc.
Health
Performance
5.6
Risk
Sell
Buy
Curious about the Scores? Learn more.

Charles River Laboratories International, Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

16.07.2026
On shaky ground. Struggling to find a clear direction.
25.06.2026
Signs of control returning. Still shaky, but not chaos.
09.06.2026
Slight bounce. Could be noise – or a comeback brewing.
20.08.2025
Climbing out. Risks fading, but not out of the woods.
CRL
Charles River Laboratories International, Inc.
219.40
-0.14%
5.6
Sell
Buy
Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Charles River Laboratories International, Inc. do? Business model and key facts

Get the full picture of Charles River Laboratories International, Inc.: what it builds, where it operates, and how it makes money.

Charles River Laboratories International, Inc. Profile

Sector: Healthcare

Industry: Medical - Diagnostics & Research

Employees (FY): 19700

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

shop
Company facts
Birgit Girshick
CEO
19700
Employees worldwide
shop
Performance
46.67%
Last 12 months
-43.01%
Last 5 years
shop
Growth
$4.02B
Revenue year
$-142,163,000
Net income
shop
Valuation
$10.81B
Market Cap
-69.99
Price/Earnings Ratio

Stocks related to Charles River Laboratories International, Inc.

Selected based on industry alignment and relative market positioning.

RVTY
Revvity, Inc.
110.52
+3.83%
4.5
Sell
Buy
Revvity, Inc.
ICLR
ICON Public Limited Company
166.62
+0.26%
7.7
Sell
Buy
ICON Public Limited Company
MEDP
Medpace Holdings, Inc.
531.67
+0.71%
5.6
Sell
Buy
Medpace Holdings, Inc.
QGEN
Qiagen N.V.
40.53
+0.12%
5.3
Sell
Buy
Qiagen N.V.
TWST
Twist Bioscience Corporation
95.86
+9.62%
8.6
Sell
Buy
Twist Bioscience Corporation

Events and news impacting Charles River Laboratories International, Inc. stock

Earnings, coporate decisions and industry developments that can affect the share price.

Charles River Laboratories International, Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.